Inventiva is a clinical-stage biopharmaceutical company developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH), a progressive chronic liver disease characterized by fat accumulation, inflammation, and fibrosis that can lead to cirrhosis and liver failure. The company's lead candidate is lanifibranor, a small molecule that targets peroxisome proliferator-activated receptors to reduce inflammation, fibrosis, and improve metabolic function in MASH patients ranging from non-cirrhotic disease through compensated cirrhosis. Inventiva generates revenue through milestone payments from development and commercialization partnerships with regional collaborators and from the asset sale of discontinued programs, and will derive revenue from lanifibranor product sales and territorial royalties upon commercialization.